#Germany #Grünenthal #Aachen #Kyowa Kirin #Grünenthal Meds

Grünenthal Fully Acquires Grünenthal Meds

In a significant move, Grünenthal has announced the complete acquisition of "Grünenthal Meds" by obtaining the remaining 49% stake from Kyowa Kirin International. This acquisition marks a pivotal moment for Grünenthal, as it allows the company to take full control over the joint venture that was formed in 2023. This strategic decision is poised to bolster Grünenthal's standing in the global pharmaceutical landscape, where they aim to make a lasting impact in the field of pain management and related treatments.

Grünenthal Meds was established as a collaborative effort between Grünenthal, holding 51% of the partnership, and Kyowa Kirin International, which contributed 49%. Since its inception, the joint venture concentrated on marketing established medicine brands, accumulating a robust portfolio valued at approximately €170 million across six therapeutic areas. The product lineup includes notable medications such as Abstral® and PecFent® for managing breakthrough cancer pain, Moventig® for opioid-induced constipation, and Adcal-D3® designed to support bone health in patients with osteoporosis.

Gabriel Baertschi, CEO of Grünenthal, elaborated on the impact of this acquisition, stating, "Thanks to the dedication and excellence of our teams, we successfully managed a diverse portfolio and harnessed synergies across our infrastructure. This acquisition confirms our ability to effectively carry out complex integrations and achieve substantial growth."

The acquisition process encompasses the management of over 200 marketing authorizations and approximately 150 product-country combinations. Furthermore, Grünenthal is facilitating several technology transfers in conjunction with numerous partners and contract manufacturers. The company anticipates completing the integration phase by June 2026. Following this, it plans to distribute the Grünenthal Meds portfolio through its affiliates in significant European markets and collaborate with international partners across additional territories.

This acquisition was made possible due to a pre-existing option agreed upon with Kyowa Kirin International at the onset of the joint venture. It aligns with Grünenthal's long-term growth objectives and further diversifies its extensive portfolio. Over the past several years, the company has actively engaged in numerous acquisitions with an overarching transaction value surpassing €2.3 billion, significantly enhancing its operational capabilities and market presence.

Grünenthal, headquartered in Aachen, Germany, stands as a global frontrunner in the pain management sector, dedicated to delivering innovative solutions and advanced therapies targeting diverse health challenges. The company's mission revolves around transforming lives positively by focusing on innovation and patient-centered care. With its operations spanning across 28 countries and availability in roughly 100 territories, Grünenthal remains committed to advancing its vision of a world free from pain.

As they look ahead, Grünenthal reaffirms its commitment to excellence in pharmaceutical innovation and strategic partnerships that enhance its product offerings, aiming to set new benchmarks in healthcare around the globe. The acquisition of Grünenthal Meds is a decisive step toward realizing this vision, signifying not just a merger of businesses, but a comprehensive strategy to uplift the standards of patient care and pain management.

In conclusion, the acquisition of Grünenthal Meds is a testament to Grünenthal’s growth strategy and solidifies its position in the competitive pharmaceutical market. The next few years are set to be pivotal as they integrate their new assets and enhance their service offerings, all while remaining focused on their core mission of improving the lives of individuals suffering from pain and related conditions.